Baysal, Bora E.Sharma, ShraddhaHashemikhabir, SeyedsasanJanga, Sarath Chandra2018-02-282018-02-282017-07Baysal, B. E., Sharma, S., Hashemikhabir, S., & Janga, S. C. (2017). RNA Editing in Pathogenesis of Cancer. Cancer Research, 77(14), 3733–3739. https://doi.org/10.1158/0008-5472.CAN-17-0520https://hdl.handle.net/1805/15317Several adenosine or cytidine deaminase enzymes deaminate transcript sequences in a cell type or environment-dependent manner by a programmed process called RNA editing. RNA editing enzymes catalyze A>I or C>U transcript alterations and have the potential to change protein coding sequences. In this brief review, we highlight some recent work that shows aberrant patterns of RNA editing in cancer. Transcriptome sequencing studies reveal increased or decreased global RNA editing levels depending on the tumor type. Altered RNA editing in cancer cells may provide a selective advantage for tumor growth and resistance to apoptosis. RNA editing may promote cancer by dynamically recoding oncogenic genes, regulating oncogenic gene expression by noncoding RNA and miRNA editing, or by transcriptome scale changes in RNA editing levels that may affect innate immune signaling. Although RNA editing markedly increases complexity of the cancer cell transcriptomes, cancer-specific recoding RNA editing events have yet to be discovered. Epitranscriptomic changes by RNA editing in cancer represent a novel mechanism contributing to sequence diversity independently of DNA mutations. Therefore, RNA editing studies should complement genome sequence data to understand the full impact of nucleic acid sequence alterations in cancer.enPublisher PolicyRNA editingcanceradenosine deaminasesArticle